Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
Brief Summary: This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to \<130 mmHg (intensive control) versus \<145 mmHg (standard control) slows/halts the progression of deterioration of mobility and cognitive function linked to white-matter disease (also known as white-matter hyperintensity or WMH) in patients with normal or mildly impaired mobility and cognition in subjects with detectable cerebrovascular disease (\>0.5% WMH fraction of intracranial contents). The study patients will be enrolled and randomized to one of two levels of ambulatory blood pressure control (intensive to achieve a goal 24-hour systolic blood pressure of \< 130 mmHg or standard to achieve a goal 24-hour systolic blood pressure of \< 145 mmHg) for a total of 36 months.


Options:
A: Intervention Type: DRUG; Name: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atenolol/HCTZ/Trandolapril; Assigned to Arm(s): N/A
B: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
C: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard
D: Arm Label: Intensive Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Arm Label: Usual Strategy; Type: OTHER; Interventions: Drug: Triatec 10 mg, Drug: Triatec HCT 5, Drug: Lasix 25, Drug: Micardis 80 mg, Drug: Micardis plus 80/12.5, Drug: Catapresan TTS 2, Drug: Norvasc 10 mg, Drug: Triatec 5 mg, Drug: Pluscor | Intervention Type: DRUG; Name: Triatec 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec HCT 5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Lasix 25; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis 80 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Micardis plus 80/12.5; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Catapresan TTS 2; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Norvasc 10 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Triatec 5 mg; Assigned to Arm(s): Intensive Strategy, Usual Strategy | Intervention Type: DRUG; Name: Pluscor; Assigned to Arm(s): Intensive Strategy, Usual Strategy

Answer: C